Delta-9-Tetrahydrocannabinol

Delta-9-Tetrahydrocannabinol
Product Name Delta-9-Tetrahydrocannabinol
CAS No.: 1972-08-3
Catalog No.: CFN91898
Molecular Formula: C21H30O2
Molecular Weight: 314.46 g/mol
Purity: >=98%
Type of Compound: Phenols
Physical Desc.: Powder
Targets: Sodium Channel | ATPase | Potassium Channel | IL Receptor | TGF-β/Smad
Source: The herbs of Cannabis sativa
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price:
Delta 9-tetrahydrocannabinol(THC) induces dopamine release in the human striatum, this allows new directions in research on the effects of THC in neuropsychiatric disorders, such as schizophrenia. THC demonstrates an analgesic effect in patients experiencing cancer pain, it has antiemetic effect in patients receiving cancer chemotherapy. THC shows neuroprotection against ouabain-induced in vivo excitotoxicity, it promotes tumor growth by inhibiting antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Food Sci Biotechnol.2023, 32(7):997-1003.
  • Int J Mol Sci.2017, 19(1)
  • Int J Med Sci.2020, 17(5):626-631
  • Environ Toxicol.2021, 36(9):1848-1856.
  • ACS Pharmacol. Transl. Sci.2022, 5,7,479-490
  • Evid-Based Compl Alt2020, 7202519:13
  • Front Plant Sci.2018, 9:1424
  • Clin Exp Pharmacol Physiol.2015, 42(11):1189-97
  • Enzyme Microb Technol.2022, 161:110111.
  • J Food Sci Technol.2019, 56(5):2712-2720
  • Cannabidiol

    Catalog No: CFN99444
    CAS No: 13956-29-1
    Price: $40/20mg
    Cannabidiol hydroxyquinone

    Catalog No: CFN91619
    CAS No: 137252-25-6
    Price: Inquiry(manager@chemfaces.com)
    Epicannabidiol hydrate

    Catalog No: CFN99443
    CAS No: 139561-95-8
    Price: Inquiry(manager@chemfaces.com)
    Cannabidiolic acid

    Catalog No: CFN99356
    CAS No: 1244-58-2
    Price: $413/5mg
    Delta-9-Tetrahydrocannabinolic acid

    Catalog No: CFN91872
    CAS No: 23978-85-0
    Price: Inquiry(manager@chemfaces.com)
    Delta-9-Tetrahydrocannabinol

    Catalog No: CFN91898
    CAS No: 1972-08-3
    Price: Inquiry(manager@chemfaces.com)
    Cannabinol

    Catalog No: CFN92993
    CAS No: 521-35-7
    Price: Inquiry(manager@chemfaces.com)
    Delta-9-Tetrahydrocannabivarinic acid

    Catalog No: CFN92992
    CAS No: 39986-26-0
    Price: Inquiry(manager@chemfaces.com)
    Cannabivarin

    Catalog No: CFN89306
    CAS No: 33745-21-0
    Price: Inquiry(manager@chemfaces.com)
    Tetrahydrocannabivarin

    Catalog No: CFN96627
    CAS No: 31262-37-0
    Price: Inquiry(manager@chemfaces.com)
    Biological Psychiatry, 2005, 57(6):594-608.
    Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.[Pubmed: 15780846]
    Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders.
    METHODS AND RESULTS:
    In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-Tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated schizophrenia patients. These data were compared with effects in healthy subjects reported elsewhere. Delta-9-Tetrahydrocannabinol transiently increased 1) learning and recall deficits; 2) positive, negative, and general schizophrenia symptoms; 3) perceptual alterations; 4) akathisia, rigidity, and dyskinesia; 5) deficits in vigilance; and 6) plasma prolactin and cortisol. Schizophrenia patients were more vulnerable to Delta-9-THC effects on recall relative to control subjects. There were no serious short- or long-term adverse events associated with study participation.
    CONCLUSIONS:
    Delta-9-Tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia. These data do not provide a reason to explain why schizophrenia patients use or misuse cannabis. Furthermore, Delta-9-THC might differentially affect schizophrenia patients relative to control subjects. Finally, the enhanced sensitivity to the cognitive effects of Delta-9-THC warrants further study into whether brain cannabinoid receptor dysfunction contributes to the pathophysiology of the cognitive deficits associated with schizophrenia.
    Neuropsychopharmacology. 2009 Feb;34(3):759-66.
    Delta-9-tetrahydrocannabinol induces dopamine release in the human striatum.[Pubmed: 18754005]
    The influence of cannabis on mental health receives growing scientific and political attention. An increasing demand for treatment of cannabis dependence has refueled the discussion about the addictive potential of cannabis. A key feature of all addictive drugs is the ability to increase synaptic dopamine levels in the striatum, a mechanism involved in their rewarding and motivating effects. However, it is currently unknown if cannabis can stimulate striatal dopamine neurotransmission in humans.
    METHODS AND RESULTS:
    Here we show that Delta-9-Tetrahydrocannabinol (THC), the main psychoactive component in cannabis, induces dopamine release in the human striatum. Using the dopamine D(2)/D(3) receptor tracer [(11)C]raclopride and positron emission tomography in seven healthy subjects, we demonstrate that THC inhalation reduces [(11)C]raclopride binding in the ventral striatum and the precommissural dorsal putamen but not in other striatal subregions. This is consistent with an increase in dopamine levels in these regions.
    CONCLUSIONS:
    These results suggest that THC shares a potentially addictive property with other drugs of abuse. Further, it implies that the endogenous cannabinoid system is involved in regulating striatal dopamine release. This allows new directions in research on the effects of THC in neuropsychiatric disorders, such as schizophrenia.
    J Clin Pharmacol. 1975 Feb-Mar;15(2-3):139-43.
    Analgesic effect of delta-9-tetrahydrocannabinol.[Pubmed: 1091664]

    METHODS AND RESULTS:
    A preliminary trial of oral Delta-9-Tetrahydrocannabinol (THC) demonstrated an analgesic effect of the drug in patients experiencing cancer pain. Placebo and 5, 10, 15, and 20 mg THC were administered double blind to ten patients. Pain relief significantly superior to placebo was demonstrated at high dose levels (15 and 20 mg).
    CONCLUSIONS:
    At these levels, substantial sedation and mental clouding were reported.
    N Engl J Med. 1975 Oct 16;293(16):795-7.
    Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.[Pubmed: 1099449]
    Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents.
    METHODS AND RESULTS:
    Oral Delta-9-Tetrahydrocannabinol was compared with placebo in a controlled, randomized, "double-blind" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo (P less than 0.001). No patient vomited while experiencing a subjective "high".
    CONCLUSIONS:
    Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducting vomiting caused by chemotherapeutic agents.
    J Neurosci. 2001 Sep 1;21(17):6475-9.
    Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.[Pubmed: 11517236]
    Excitotoxicity is a paradigm used to explain the biochemical events in both acute neuronal damage and in slowly progressive, neurodegenerative diseases.
    METHODS AND RESULTS:
    Here, we show in a longitudinal magnetic resonance imaging study that Delta-9-Tetrahydrocannabinol(Delta(9)-THC), the main active compound in marijuana, reduces neuronal injury in neonatal rats injected intracerebrally with the Na(+)/K(+)-ATPase inhibitor ouabain to elicit excitotoxicity. In the acute phase Delta(9)-THC reduced the volume of cytotoxic edema by 22%. After 7 d, 36% less neuronal damage was observed in treated rats compared with control animals. Coadministration of the CB(1) cannabinoid receptor antagonist SR141716 prevented the neuroprotective actions of Delta(9)-THC, indicating that Delta(9)-THC afforded protection to neurons via the CB(1) receptor. In Delta(9)-THC-treated rats the volume of astrogliotic tissue was 36% smaller. The CB(1) receptor antagonist did not block this effect.
    CONCLUSIONS:
    These results provide evidence that the cannabinoid system can serve to protect the brain against neurodegeneration.
    J Immunol. 2000 Jul 1;165(1):373-80.
    Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.[Pubmed: 10861074]
    In this study, we show that Delta-9-Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, suppresses host immune reactivity against lung cancer.
    METHODS AND RESULTS:
    In two different weakly immunogenic murine lung cancer models, intermittent administration of THC (5 mg/kg, four times/wk i.p. for 4 wk) led to accelerated growth of tumor implants compared with treatment with diluent alone. In contrast to our findings in immunocompetent mice, THC did not affect tumor growth in tumor-bearing SCID mice. The immune inhibitory cytokines, IL-10 and TGF-beta, were augmented, while IFN-gamma was down-regulated at both the tumor site and in the spleens of THC-treated mice. Administration of either anti-IL-10- or anti-TGF-beta-neutralizing Abs prevented the THC-induced enhancement in tumor growth. Both APC and T cells from THC-treated mice showed limited capacities to generate alloreactivity. Furthermore, lymphocytes from THC-treated mice transferred the effect to normal mice, resulting in accelerated tumor growth similar to that seen in the THC-treated mice. THC decreased tumor immunogenicity, as indicated by the limited capacity for tumor-immunized, THC-treated mice to withstand tumor rechallenge. In vivo administration of a specific antagonist of the CB2 cannabinoid receptor also blocked the effects of THC.
    CONCLUSIONS:
    Our findings suggest the THC promotes tumor growth by inhibiting antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
    Pilosidine

    Catalog No: CFN95110
    CAS No: 229971-57-7
    Price: $413/5mg
    Yuanhuanin

    Catalog No: CFN95127
    CAS No: 83133-14-6
    Price: $318/5mg
    3-O-[5'''-O-feruloyl-beta-D-apiofuranosyl(1'''->2'')-beta-D-glucopyranosyl] rhamnocitrin

    Catalog No: CFN95154
    CAS No: 148210-00-8
    Price: $413/5mg
    Isosaponarin 2''-O-glucoside (Isovitexin-2''-4'-di-O-beta-D-glucoside)

    Catalog No: CFN95296
    CAS No: 63316-27-8
    Price: $318/10mg
    Rosmarinyl glucoside

    Catalog No: CFN95297
    CAS No: 910028-78-3
    Price: $413/5mg
    3-O-Methylellagic acid 3'-O-alpha-rhamnopyranoside

    Catalog No: CFN95375
    CAS No: 352280-34-3
    Price: $413/5mg
    Methyl 2-hydroxy-3,4-dimethoxybenzoate

    Catalog No: CFN95383
    CAS No: 6395-23-9
    Price: $268/5mg
    10-O-trans-p-Feruloylscandoside

    Catalog No: CFN95392
    CAS No: 1428268-72-7
    Price: $318/10mg
    Dihydroconfertin

    Catalog No: CFN95523
    CAS No: 68832-40-6
    Price: $318/5mg
    Methyl ganoderenate F

    Catalog No: CFN95573
    CAS No: N/A
    Price: $413/5mg